The stock of Viking Therapeutics Inc (VKTX) has gone down by -4.55% for the week, with a 2.54% rise in the past month and a 317.15% rise in the past quarter. The volatility ratio for the week is 6.71%, and the volatility levels for the past 30 days are 8.74% for VKTX. The simple moving average for the last 20 days is 5.21% for VKTX stock, with a simple moving average of 205.44% for the last 200 days.
Is It Worth Investing in Viking Therapeutics Inc (NASDAQ: VKTX) Right Now?
Company’s 36-month beta value is 1.12.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VKTX is 99.62M, and currently, short sellers hold a 11.18% ratio of that floaft. The average trading volume of VKTX on April 09, 2024 was 6.59M shares.
VKTX) stock’s latest price update
Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by -0.75relation to previous closing price of 76.45. Nevertheless, the company has seen a -4.55% plunge in its stock price over the last five trading sessions. The Motley Fool reported 2024-04-08 that Viking aims to challenge big pharma players Eli Lilly and Novo Nordisk in the multibillion-dollar weight loss drug market. It recently reported excellent clinical trial results for its injectable and oral tablet weight loss candidates.
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with Oppenheimer repeating the rating for VKTX by listing it as a “Outperform.” The predicted price for VKTX in the upcoming period, according to Oppenheimer is $138 based on the research report published on March 26, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $110. The rating they have provided for VKTX stocks is “Buy” according to the report published on March 07th, 2024.
Oppenheimer gave a rating of “Outperform” to VKTX, setting the target price at $116 in the report published on February 28th of the current year.
VKTX Trading at 37.01% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.67% of loss for the given period.
Volatility was left at 8.74%, however, over the last 30 days, the volatility rate increased by 6.71%, as shares surge +5.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +252.77% upper at present.
During the last 5 trading sessions, VKTX fell by -4.55%, which changed the moving average for the period of 200-days by +253.59% in comparison to the 20-day moving average, which settled at $72.32. In addition, Viking Therapeutics Inc saw 307.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from Lian Brian, who sale 45,000 shares at the price of $29.90 back on Feb 09 ’24. After this action, Lian Brian now owns 2,139,882 shares of Viking Therapeutics Inc, valued at $1,345,500 using the latest closing price.
Lian Brian, the President & CEO of Viking Therapeutics Inc, sale 269,079 shares at $26.87 during a trade that took place back on Feb 08 ’24, which means that Lian Brian is holding 2,184,882 shares at $7,230,784 based on the most recent closing price.
Stock Fundamentals for VKTX
The total capital return value is set at -0.29. Equity return is now at value -34.79, with -31.99 for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -58.23. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 106.58.
Currently, EBITDA for the company is -100.53 million with net debt to EBITDA at 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.19.
Conclusion
In a nutshell, Viking Therapeutics Inc (VKTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
